This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
follicular-lymphoma
Follicular Lymphoma
Follicular lymphoma is the most common indolent B-cell lymphoma; t(14;18) BCL-2-IGH in ~85% drives apoptosis resistance; EZH2 Y641 in ~25% silences tumor suppressors. Rituximab+bendamustine or R-CHOP are standard; tazemetostat is approved for EZH2-mutant relapsed/refractory FL.
Entry Metadata
| Field | Value |
|---|---|
| ID | follicular-lymphoma |
| Name | Follicular Lymphoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344. · PubMed 28976863
- Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma (E7438-G-003): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1433-1442. · PubMed 33035457